EE99 Cost-Utility Analysis of 13-Valent Pneumococcal Conjugate Vaccine in the Immunization of Children Under Five Years for the Prevention of Invasive Pneumococcal Disease and Pneumonia in the Brazilian Public Healthcare System

Abstract

Streptococcus pneumoniae (or pneumococcus) infections are still important causes of morbidity and mortality. In 2015, despite the decrease in the burden of pneumococcal disease due to the use of conjugate vaccines, an estimated 393,000 deaths worldwide in children under 5 years old were due to pneumonia. The aim of this analysis is to compare utility and costs between 13-valent pneumococcal conjugate vaccine versus the 10-valent for children under five years old.